-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Editor: Wu Bin
As the new crown virus continues to mutate, the US pharmaceutical giant accidentally "lay the gun".
The FDA explained in the statement that because of the increase in mutant viruses that are resistant to bamlanivimab, only using the drug to treat patients with new coronary pneumonia infection "the risk of treatment failure is increasing.
The FDA explained in the statement that because of the increase in mutant viruses that are resistant to bamlanivimab, only using the drug to treat patients with new coronary pneumonia infection "the risk of treatment failure is increasing.
It is worth noting that before the FDA announced on Friday that the emergency use authorization of Eli Lilly's new crown antibody drug was revoked, Eli Lilly had already admitted that due to some mutant viruses circulating in the United States, the effect of treatment with bamlanivimab alone has declined, and Eli Lilly will Focus on promoting the cocktail therapy of bamlanivimab and the company's second antibody drug etesevimab.
Although the emergency authorization of the new crown antibody drug bamlanivimab has been revoked, the FDA emphasized that the REGEN-COV antibody cocktail therapy, Eli Lilly bamlanivimab and etesevimab cocktail therapy are still available.
